This inventor holds 1 USPTO granted patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Matthew H McNiell: Innovator in Pharmaceutical Compounds
Introduction
Matthew H McNiell is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit apoptosis signal-regulating kinase 1 (ASK1). His work is crucial in advancing therapeutic options for various diseases.
Latest Patents
Matthew holds a patent for "Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1." This invention relates to ASK1 inhibiting compounds, which are essential for developing new pharmaceutical compositions and methods of treatment. The patent outlines the formula for these compounds and their potential applications in medicine.
Career Highlights
Matthew is currently associated with Takeda Pharmaceutical Company Limited, where he continues to innovate in the pharmaceutical sector. His expertise in developing ASK1 inhibitors showcases his commitment to improving health outcomes through scientific research.
Collaborations
Matthew has collaborated with talented individuals such as Angie Vassar and Edcon Chang. These partnerships enhance the research and development process, leading to more effective pharmaceutical solutions.
Conclusion
Matthew H McNiell is a distinguished inventor whose work in pharmaceutical compounds has the potential to impact the medical field significantly. His contributions to ASK1 inhibitors exemplify the importance of innovation in healthcare.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile